Corresponding Author: Oskar Hansson, MD, PhD, Memory Clinic, Skåne University Hospital, SE-20502 Malmö, Sweden (Oskar.Hansson@med.lu.se).
Accepted for Publication: June 22, 2020.
Published Online: July 28, 2020. doi:10.1001/jama.2020.12134
Author Contributions: Drs Hansson and Palmqvist had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Palmqvist and Janelidze contributed equally as first authors. Drs Hansson and Reiman (nonequally) contributed as senior authors.
Concept and design: Hansson.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Palmqvist, Janelidze, Hansson.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Palmqvist, Janelidze, Su, Chen, Strandberg.
Obtained funding: Palmqvist, Zetterberg, Mattsson-Carlgren, Beach, Blennow, Dage, Reiman, Hansson.
Administrative, technical, or material support: Palmqvist, Lopera, Strandberg, Smith, Villegas, Sepulveda-Falla, Chai, Beach, Dage, Reiman, Hansson.
Supervision: Dage, Reiman, Hansson.
Conflict of Interest Disclosures: Dr Quiroz reported receiving grants from the National Institutes of Health (NIH) and Massachusetts General Hospital. Dr Zetterberg reported receiving grants from The Knut and Alice Wallenberg Foundation, European Research Council, and Swedish Research Council; receiving personal fees from Samumed, Roche Diagnostics, CogRx, Wave, Alzecure, and Biogen; and that he is cofounder of Brain Biomarker Solutions in Gothenburg AB. Dr Lopera reported receiving grants from the NIH and Genentech/Roche/Banner and receiving personal fees from the NIH. Dr Su reported receiving grants from the NIH, the State of Arizona, BrightFocus Foundation, and Alzheimer's Association and receiving personal fees from Green Valley Pharmaceutical LLC. Dr Chai reported a patent to pTau217 assay and its use, antibodies pending. Dr Beach reported receiving grants from the State of Arizona; receiving personal fees from Prothena Biosciences, Vivid Genomics, and Avid Radiopharmaceuticals; and holding stock options with Vivid Genomics. Dr Blennow reported receiving personal fees from Abcam, Axon, Biogen, Lilly, MagQu, Novartis, and Roche Diagnostics and that he is cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Dr Dage reported a patent pending for compounds and methods targeting human tau. Dr Reiman reported receiving grants from National Institute on Aging and the State of Arizona; receiving philanthropic funding from the Banner Alzheimer’s Foundation, Sun Health Foundation, and Roche/Roche Diagnostics; receiving personal fees from Alkahest, Alzheon, Aural Analytics, Denali, Green Valley, MagQ, Takeda/Zinfandel, United Neuroscience; that he has since submission of manuscript become a cofounder of AlzPath, which aims to further develop P-tau217 and fluid biomarkers and advance their use in research, drug development, and clinical settings; holding a patent owned by Banner Health for a strategy to use biomarkers to accelerate evaluation of Alzheimer prevention therapies; and that he is a principal investigator of prevention trials that include research agreements with Genentech/Roche and Novartis/Amgen, PET studies that include research agreements with Avid/Lilly, and several NIH and Foundation-supported research studies. Dr Hansson reported receiving grants from Roche, Biogen, and Pfizer and receiving nonfinancial support from GE Healthcare, AVID Radiopharmaceuticals, and Euroimmun. No other disclosures were reported.
Funding/Support: Work at the authors’ research centers was supported by the Swedish Research Council, the Knut and Alice Wallenberg Foundation, Region Skåne, the Marianne and Marcus Wallenberg Foundation, the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, The Parkinson Foundation of Sweden, The Parkinson Research Foundation, the Skåne University Hospital Foundation, the Greta and Johan Kock Foundation, the Swedish federal government under the ALF agreement, the NIH Office of the Director, the Alzheimer’s Association, the Massachusetts General Hospital Executive Committee on Research, the National Institute of Neurological Disorders and Stroke (U24 NS072026), National Institute on Aging (P30 AG19610), the Arizona Department of Health Services, the Michael J. Fox Foundation for Parkinson’s Research, Banner Alzheimer’s Foundation, Sun Health Foundation, the State of Arizona, and Eli Lilly and Company. Eli Lilly and Company provided material support for P-tau217 sample analysis and salary for Dr Chai, Mr Proctor, and Dr Dage. The precursor of 18F-flutemetamol was provided by GE Healthcare and the precursor of 18F-RO948 was provided by Roche.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. In addition, Eli Lilly and company had the opportunity to review the manuscript before submission but had no veto power. Dr Hansson made the final decision to submit the manuscript to JAMA for publication.
Meeting Presentation: This study was presented online at the Alzheimer's Association International Conference; July 28, 2020.
2. Global Action Plan on the Public Health Response to Dementia 2017-2025. World Health Organization; 2017.
5.Rabinovici
GD , Gatsonis
C , Apgar
C ,
et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia.
JAMA. 2019;321(13):1286-1294. doi:
10.1001/jama.2019.2000PubMedGoogle ScholarCrossref 6.Ossenkoppele
R , Rabinovici
GD , Smith
R ,
et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders.
JAMA. 2018;320(11):1151-1162. doi:
10.1001/jama.2018.12917PubMedGoogle ScholarCrossref 13.Janelidze
S , Mattsson
N , Palmqvist
S ,
et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia.
Nat Med. 2020;26(3):379-386. doi:
10.1038/s41591-020-0755-1PubMedGoogle ScholarCrossref 14.Thijssen
EH , La Joie
R , Wolf
A ,
et al; Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) Investigators. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration.
Nat Med. 2020;26(3):387-397. doi:
10.1038/s41591-020-0762-2PubMedGoogle ScholarCrossref 16.National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease.
Neurobiol Aging. 1997;18(4)(suppl):S1-S2.
PubMedGoogle ScholarCrossref 17.Mirra
SS , Heyman
A , McKeel
D ,
et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD), II: standardization of the neuropathologic assessment of Alzheimer’s disease.
Neurology. 1991;41(4):479-486. doi:
10.1212/WNL.41.4.479PubMedGoogle ScholarCrossref 19. Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition). American Psychiatric Association; 2013.
20.Tariot
PN , Lopera
F , Langbaum
JB ,
et al; Alzheimer’s Prevention Initiative. The Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease Trial: a study of crenezumab versus placebo in preclinical
PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer’s disease, including a placebo-treated noncarrier cohort.
Alzheimers Dement (N Y). 2018;4:150-160.
PubMedGoogle Scholar 21.Morris
JC , Heyman
A , Mohs
RC ,
et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD), I: clinical and neuropsychological assessment of Alzheimer’s disease.
Neurology. 1989;39(9):1159-1165. doi:
10.1212/WNL.39.9.1159PubMedGoogle ScholarCrossref 22.Palmqvist
S , Insel
PS , Stomrud
E ,
et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease.
EMBO Mol Med. 2019;11(12):e11170. doi:
10.15252/emmm.201911170PubMedGoogle Scholar 23.Mielke
MM , Hagen
CE , Xu
J ,
et al. Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography.
Alzheimers Dement. 2018;14(8):989-997. doi:
10.1016/j.jalz.2018.02.013PubMedGoogle ScholarCrossref 24.Leuzy
A , Smith
R , Ossenkoppele
R ,
et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders.
JAMA Neurol. Published online May 11, 2020. doi:
10.1001/jamaneurol.2020.0989PubMedGoogle Scholar 25.DeLong
ER , DeLong
DM , Clarke-Pearson
DL . Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.
Biometrics. 1988;44(3):837-845. doi:
10.2307/2531595PubMedGoogle ScholarCrossref 26.Quiroz
YT , Zetterberg
H , Reiman
EM ,
et al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer’s disease kindred: a cross-sectional and longitudinal cohort study.
Lancet Neurol. 2020;19(6):513-521. doi:
10.1016/S1474-4422(20)30137-XPubMedGoogle ScholarCrossref 27.Barthélemy
NR , Bateman
RJ , Hirtz
C ,
et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification.
Alzheimers Res Ther. 2020;12(1):26. doi:
10.1186/s13195-020-00596-4PubMedGoogle ScholarCrossref 28.Barthélemy
NR , Li
Y , Joseph-Mathurin
N ,
et al; Dominantly Inherited Alzheimer Network. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease.
Nat Med. 2020;26(3):398-407. doi:
10.1038/s41591-020-0781-zPubMedGoogle ScholarCrossref 29.Mattsson-Carlgren
N , Andersson
E , Janelidze
S ,
et al. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer’s disease.
Sci Adv. 2020;6(16):eaaz2387. doi:
10.1126/sciadv.aaz2387PubMedGoogle Scholar 31.Palmqvist
S , Insel
PS , Zetterberg
H ,
et al; Alzheimer’s Disease Neuroimaging Initiative; Swedish BioFINDER study. Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer’s disease: cross-validation study of practical algorithms.
Alzheimers Dement. 2019;15(2):194-204. doi:
10.1016/j.jalz.2018.08.014PubMedGoogle ScholarCrossref 33.Chatterjee
P , Goozee
K , Sohrabi
HR ,
et al. Association of plasma neurofilament light chain with neocortical amyloid-β load and cognitive performance in cognitively normal elderly participants.
J Alzheimers Dis. 2018;63(2):479-487. doi:
10.3233/JAD-180025PubMedGoogle ScholarCrossref 34.Mattsson
N , Andreasson
U , Zetterberg
H , Blennow
K ; Alzheimer’s Disease Neuroimaging Intiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease.
JAMA Neurol. 2017;74(5):557-566. doi:
10.1001/jamaneurol.2016.6117PubMedGoogle ScholarCrossref 38.Sato
C , Barthelemy
NR , Mawuenyega
KG ,
et al Tau kinetics in neurons and the human central nervous system.
Neuron. 2018;97(6):1284-1298.
Google ScholarCrossref 39.Kuhlmann
J , Andreasson
U , Pannee
J ,
et al; IFCC Working Group on Standardization of CSF proteins (WG-CSF). CSF Aβ
1-42—an excellent but complicated Alzheimer’s biomarker—a route to standardisation.
Clin Chim Acta. 2017;467:27-33. doi:
10.1016/j.cca.2016.05.014PubMedGoogle ScholarCrossref